WCLC 2022 – Helmut Popper
Helmut Popper talks about the characteristics of the recently defined molecular subtypes of small-cell lung cancer (SCLC), outlines if this subtyping is suitable for therapeutic decision-making and gives an overview about potential new therapeutic targets in the field of SCLC.
Here is the full WCLC 2022 report.
More posts
Immune-based strategies are raising hope in small-cell tumors
Immune-based strategies are raising hope in small-cell tumors DeLLphi-300: tarl
Stage I-III disease: surgical and systemic options
Stage I-III disease: surgical and systemic options SLR as new standard of care
Promising findings across oncogenic targets
Promising findings across oncogenic targets Amivantamab plus lazertinib in EGFR
Preface – WCLC 2022
Preface – WCLC 2022 © Private – Michael Thomas, MD, PhD, Head of the Depar
